Project Grant F31AI200281
Award Date 12/8/26
Completion Date 8/16/28
Dollars Obligated $100K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Lafayette, IN, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Montana State University $571,859 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify viral proteins driving orthobunyavirus neuropathogenesis. The research will leverage differences in neuropathogenic phenotypes among California Serogroup orthobunyaviruses—La Crosse virus (LACV), Jamestown Canyon virus (JCV), and Inkoo virus (INKV)—to determine which viral proteins mediate...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $771,510 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to profile La Crosse virus genetic diversity in human neuroinvasive disease cases and peridomestic mosquitoes in Western North Carolina. The research establishes and executes a prospective cohort study collecting serum and cerebrospinal fluid samples from La Crosse virus patients...
- The National Institute of Allergy and Infectious Diseases, an operating division of the Department of Health and Human Services, awarded Louisiana State University $412,500 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify RNAi-independent antiviral genes through biased genetic screening in Caenorhabditis elegans. The funded research addresses antiviral mechanisms that function independently of RNAi (RNA interference), the predominant...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $498,154 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into signaling mechanisms governing chimeric antigen receptor T cell activation. The research addresses a critical gap in understanding how CAR T cells recognize and eliminate target cells while avoiding off-target activation and collateral damage. CAR T cells express artificial receptors...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $442,500 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimicrobial agents derived from aapeptide biomaterials targeting drug-resistant bacterial infections. The research addresses antimicrobial resistance identified by the World Health Organization as a major twenty-first-century threat. Purdue will develop small-molecule scorpion-like amphipathic...
- The National Institute of Allergy and Infectious Diseases awarded the La Jolla Institute for Immunology $923,708 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a therapeutic antibody cocktail against New World arenaviruses. The work extends through March 31, 2031, and is performed in La Jolla, California. The project develops monoclonal antibody therapies targeting New World arenaviruses including Machupo, Junin, Guanarito, Sabia, and...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $749,736 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the biology of picobirnaviruses. The project seeks to establish culture systems and identify the host organisms of picobirnaviruses (PBVs), small double-stranded, bisegmented RNA viruses detected at high prevalence in the human enteric tract and linked to type 1 diabetes and...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $100,228 on December 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of G-quadruplex DNA structures in the antigenic variation mechanism of Borrelia burgdorferi, the causative agent of Lyme disease. The research addresses the molecular mechanism by which B. burgdorferi evades host adaptive immune defenses through antigenic variation—reshaping outer...
- The National Institute of Allergy and Infectious Diseases awarded Loyola University of Chicago Health Sciences Campus $462,000 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on mechanistic understanding of influenza virus inhibition by non-canonical ISG15. The research examines how alternative splicing of the interferon-stimulated gene ISG15 produces novel transcript isoforms that inhibit influenza virus replication. The project...